| Zurich | |
| 33 | |
| Orally available small molecule drugs, called allosteric modulators, to treat a broad range of diseases. | |
| Diproglurant IR nGluRS NAM: Parkinson's disease levodopa induced Dyskinesia (PD-LID), currently in Phase II development, partially founded by Mychael J.Fox Foundation. Diproglurant ER nGluRS NAM: Focal cervical dystonia, currently in Phase I development, in collaboration with Dystonia Medical Foundation. ADX71149 nGluR2n PAM: Epilepsy, currently in phase I development, partenered with Janssen Pharmaceutical. |
|
| DYER Tim | |
| www.addextherapeutics.com | |
| ADXN:SW |
Fiche créée le 10/04/2016 par 
Guillaume vue 4 fois.